FFAR2 and Hepatic fibrosis: The deletion of liver-specific FFAR2 worsens insulin resistance, causing inflammation, hypercholesterolemia and liver fibrosis, suggesting a protective effect of GPCR activity mediated by acetate and FFAR2 [118].